<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00453791</url>
  </required_header>
  <id_info>
    <org_study_id>SF2105450</org_study_id>
    <nct_id>NCT00453791</nct_id>
  </id_info>
  <brief_title>The Safety and Tolerability of GW805858 in Healthy Volunteers and Mild Asthmatics</brief_title>
  <official_title>A Randomised, Single and Repeat Dose, Double-blind, Placebo Controlled Study to Assess the Safety and Tolerability of GW805858 in Healthy Volunteers and Mild Asthmatics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be the First Time in Human Study (FTIH) aiming to assess the safety and&#xD;
      tolerability of GW805858 for both single and repeat dose. The study also aims to assess&#xD;
      safety and tolerability in mild asthmatic subjects as well as healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">February 7, 2006</start_date>
  <completion_date type="Actual">April 10, 2006</completion_date>
  <primary_completion_date type="Actual">April 10, 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability parameters will be compared between active and placebo treatment groups using summary statistics. No formal statistical analyses of the safety and tolerability data will be performed.</measure>
    <time_frame>Up to 18 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Derived GW805858 and GW288967 PK parameters will be compared between active and placebo treatment groups using summary statistics.</measure>
    <time_frame>Pre-dose, 5,20,30,45,60,90 minutes, 2,3,4,6,8,10,12,12.5,13,14, 24 hours Post-dose on Days 1 and 28.</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 1: Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive placebo followed by GW805858 with a starting dose of 150 micrograms administered using Metered Dose Inhaler (MDI).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 2: Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive GW805858 with a starting dose of 150 micrograms followed by placebo administered using MDI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 1: Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive placebo followed by GW805858 with a starting dose of 150 micrograms administered using MDI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 2: Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive GW805858 with a starting dose of 150 micrograms followed by placebo administered using MDI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving GW805858: Part 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive GW805858 1200 micrograms twice daily administered using MDI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving placebo: Part 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive placebo administered using MDI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW805858</intervention_name>
    <description>GW805858 MDI will be given with dose of 150 micrograms per metered actuation and 120 actuations per inhaler. GW805858 MDI comprises a solution of GW805858 in a liquefied hydrofluoroalkane propellant (1,1,1,2-tetrafluoroethane) which is contained in an aluminium alloy can, internally coated with a specified fluoropolymer, fitted with a metering valve.</description>
    <arm_group_label>Subjects receiving GW805858: Part 3</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 1: Part 1</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 1: Part 2</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 2: Part 1</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 2: Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo MDI will be given to the subjects.</description>
    <arm_group_label>Subjects receiving placebo: Part 3</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 1: Part 1</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 1: Part 2</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 2: Part 1</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 2: Part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women of non-child bearing potential, aged between 18 and 60 years of age&#xD;
             inclusive.&#xD;
&#xD;
          -  Body weight = 50 kg (110 lbs) for men and = 45 kg for women and Body Mass Index (BMI)&#xD;
             within the range 19.0-30.0 kg/m2 inclusive.&#xD;
&#xD;
          -  The subject is a current non-smoker who has not used any tobacco products in the last&#xD;
             year.&#xD;
&#xD;
          -  A signed and dated written informed consent is obtained for the subject.&#xD;
&#xD;
          -  The subject is able to understand and comply with protocol requirements and&#xD;
             timetables, instructions and protocol-stated restrictions.&#xD;
&#xD;
          -  If asthmatic, the subject must be a clinically stable asthmatic.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject has a history of allergy to ingredients within the inhaler.&#xD;
&#xD;
          -  The subject has received an investigational drug or participated in any other research&#xD;
             trial within 30 days, prior to the first dose of current study medication.&#xD;
&#xD;
          -  The subject has used prescription or non-prescription drugs, including vitamins,&#xD;
             herbal and dietary supplements (including St John's Wort) within 14 days prior to the&#xD;
             first dose of study medication.&#xD;
&#xD;
          -  The subject has an average weekly alcohol intake of greater than 21 units if male or&#xD;
             14 units if female.&#xD;
&#xD;
          -  The subject has any history of breathing problems (e.g. history of asthmatic&#xD;
             symptoms).&#xD;
&#xD;
          -  The subject is infected with the hepatitis B, hepatitis C, or HIV virus.&#xD;
&#xD;
          -  The subject has had a respiratory tract infection or worsening of asthma within 4&#xD;
             weeks of the start of the study.&#xD;
&#xD;
          -  The subject has a past or present disease, which as judged by the Investigator, may&#xD;
             affect the outcome of this study.&#xD;
&#xD;
          -  The subject has a history of life-threatening asthma, defined as an asthma episode&#xD;
             that required intubation and/or was associated with hypercapnea, respiratory arrest or&#xD;
             hypoxia seizures.&#xD;
&#xD;
          -  The subject has taken inhaled, nasal or dermal steroids within 4 weeks or oral&#xD;
             steroids within 8 weeks of the start of the study.&#xD;
&#xD;
          -  The subject is unable to abstain from other drugs that may interfere with the conduct&#xD;
             of the study.&#xD;
&#xD;
          -  The subject has ongoing rhinitis that requires treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SW20 0NE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>March 27, 2007</study_first_submitted>
  <study_first_submitted_qc>March 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2007</study_first_posted>
  <last_update_submitted>September 27, 2017</last_update_submitted>
  <last_update_submitted_qc>September 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GW805858</keyword>
  <keyword>MDI</keyword>
  <keyword>asthma</keyword>
  <keyword>surfactant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

